Up to one-third of all GBMs harbor the epidermal growth factor receptor (EGFR) vIII mutation resulting in a constitutively active EGFR that does not bind its ligand, but rather, promotes tumor proliferation through downstream events [142]. This evidence concerns the gene EGFR and neoplasm.